CTLA4 and cancer: For instance, MAPK signaling has been shown to suppress the expression of negative immune checkpoints such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in several cancers [18].